Form 8-K IRONWOOD PHARMACEUTICALS For: Nov 04
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Ironwood Pharma (IRWD) Tops Q3 EPS by 2c; Initiates Phase III Trial of 72 mcg Linaclotide
November 4, 2014 4:53 PM ESTIronwood Pharma (NASDAQ: IRWD) reported Q3 EPS of ($0.30), $0.02 better than the analyst estimate of ($0.32). Revenue for the quarter came in at $16.2 million versus the consensus estimate of $21.2 million.
The company also announced today the initiation of a Phase III clinical... More
